These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36379378)

  • 1. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N
    Bluemling GR; Mao S; Natchus MG; Painter W; Mulangu S; Lockwood M; De La Rosa A; Brasel T; Comer JE; Freiberg AN; Kolykhalov AA; Painter GR
    Antiviral Res; 2023 Jan; 209():105453. PubMed ID: 36379378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.
    Painter GR; Bowen RA; Bluemling GR; DeBergh J; Edpuganti V; Gruddanti PR; Guthrie DB; Hager M; Kuiper DL; Lockwood MA; Mitchell DG; Natchus MG; Sticher ZM; Kolykhalov AA
    Antiviral Res; 2019 Nov; 171():104597. PubMed ID: 31494195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.
    Warren TK; Jordan R; Lo MK; Ray AS; Mackman RL; Soloveva V; Siegel D; Perron M; Bannister R; Hui HC; Larson N; Strickley R; Wells J; Stuthman KS; Van Tongeren SA; Garza NL; Donnelly G; Shurtleff AC; Retterer CJ; Gharaibeh D; Zamani R; Kenny T; Eaton BP; Grimes E; Welch LS; Gomba L; Wilhelmsen CL; Nichols DK; Nuss JE; Nagle ER; Kugelman JR; Palacios G; Doerffler E; Neville S; Carra E; Clarke MO; Zhang L; Lew W; Ross B; Wang Q; Chun K; Wolfe L; Babusis D; Park Y; Stray KM; Trancheva I; Feng JY; Barauskas O; Xu Y; Wong P; Braun MR; Flint M; McMullan LK; Chen SS; Fearns R; Swaminathan S; Mayers DL; Spiropoulou CF; Lee WA; Nichol ST; Cihlar T; Bavari S
    Nature; 2016 Mar; 531(7594):381-5. PubMed ID: 26934220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on the antagonist Ebola: A prophylactic approach.
    Khan FN; Qazi S; Tanveer K; Raza K
    Biomed Pharmacother; 2017 Dec; 96():1513-1526. PubMed ID: 29208326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin.
    Covés-Datson EM; Dyall J; DeWald LE; King SR; Dube D; Legendre M; Nelson E; Drews KC; Gross R; Gerhardt DM; Torzewski L; Postnikova E; Liang JY; Ban B; Shetty J; Hensley LE; Jahrling PB; Olinger GG; White JM; Markovitz DM
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007595. PubMed ID: 31356611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.
    Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S
    Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ebola virus disease.
    Kilgore PE; Grabenstein JD; Salim AM; Rybak M
    Pharmacotherapy; 2015 Jan; 35(1):43-53. PubMed ID: 25630412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
    Tshiani Mbaya O; Mukumbayi P; Mulangu S
    Front Immunol; 2021; 12():721328. PubMed ID: 34526994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.
    Dhama K; Karthik K; Khandia R; Chakraborty S; Munjal A; Latheef SK; Kumar D; Ramakrishnan MA; Malik YS; Singh R; Malik SVS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():1803. PubMed ID: 30147687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.
    Banadyga L; Zhu W; Kailasan S; Howell KA; Franaszek K; He S; Siragam V; Cheng K; Yan F; Moffat E; Cao W; Leung A; Embury-Hyatt C; Aman MJ; Qiu X
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.
    Lane TR; Massey C; Comer JE; Freiberg AN; Zhou H; Dyall J; Holbrook MR; Anantpadma M; Davey RA; Madrid PB; Ekins S
    Antiviral Res; 2020 Sep; 181():104863. PubMed ID: 32682926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
    Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model.
    Toots M; Yoon JJ; Hart M; Natchus MG; Painter GR; Plemper RK
    Transl Res; 2020 Apr; 218():16-28. PubMed ID: 31945316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral effect of ranpirnase against Ebola virus.
    Hodge T; Draper K; Brasel T; Freiberg A; Squiquera L; Sidransky D; Sulley J; Taxman DJ
    Antiviral Res; 2016 Aug; 132():210-8. PubMed ID: 27350309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-γ Inhibits Ebola Virus Infection.
    Rhein BA; Powers LS; Rogers K; Anantpadma M; Singh BK; Sakurai Y; Bair T; Miller-Hunt C; Sinn P; Davey RA; Monick MM; Maury W
    PLoS Pathog; 2015; 11(11):e1005263. PubMed ID: 26562011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
    Wu W; Liu S
    Curr Top Med Chem; 2017; 17(3):361-370. PubMed ID: 27572081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.